Evidence map›Paper›PMID 36840616›Full record

ArticleJournal of diabetes science and technology2024

Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) With Type 1 Diabetes From 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg Diabetes Prospective Follow-up Database Registry.

Louisa van den Boom, Marie Auzanneau, Joachim Woelfle, Marina Sindichakis, Antje Herbst, Dagmar Meraner, Kathrin Hake, Christof Klinkert, Bettina Gohlke, Reinhard W Holl

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Louisa van den BoomDivision of Pediatrics/Pediatric Diabetology, DRK Hospital, Kirchen, Germany.ORCID 0000-0003-4823-2620
Marie AuzanneauInstitute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.ORCID 0000-0002-5906-6579
Joachim WoelfleChildren's and Adolescent's Hospital, University of Erlangen, Erlangen, Germany.
Marina SindichakisDepartment of Pediatrics, Kliniken Südostbayern, Traunstein, Germany.
Antje HerbstCentre for Paediatrics, Medical Clinic Leverkusen, Leverkusen, Germany.
Dagmar MeranerDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Kathrin HakeChildren's Hospital, Müritzklinikum Waren, Waren, Germany.
Christof KlinkertPediatric Practice, Herford, Germany.ORCID 0000-0002-6343-5744
Bettina GohlkeDivision of Pediatric Diabetology, Endocrinology, Metabolism and Obesity, Children's Hospital, University of Bonn, Bonn, Germany.
Reinhard W HollInstitute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, University of Ulm, Ulm, Germany.
Universität Ulm · DEUniversity of Bonn · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHerford Hospital · DEInnsbruck Medical University · ATKlinikum Leverkusen · DEKreisklinik Trostberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimInsulin pump, continuous glucose monitoring (CGM), and sensor augmented pump (SAP) technology have evolved continuously leading to the development of automated insulin delivery (AID) systems. Evaluation of the use of diabetes technologies in people with T1D from January 2018 to December 2021.

methodsA patient registry (Diabetes Prospective Follow-up Database [DPV]) was analyzed for use of SAP (insulin pump + CGM ≥90 days, no automated dose adjustment) and AID (HCL or LGS/PLGS). In total 46,043 people with T1D aged 0.5 to <26 years treated in 416 diabetes centers (Germany, Austria, Luxemburg, and Switzerland) were included and stratified into 4 groups A-D according to age. Additionally, TiR and HbA1c were analyzed.

resultsFrom 2018 to 2021, there was a significant increase from 28.7% to 32.9% (sensor augmented pump [SAP]) and 3.5% to 16.6% (AID) across all age groups, with the most frequent use in group A (<7 years, 38.8%-40.2% and 10.3%-28.5%). A similar increase in SAP and AID use was observed in groups B (7 to <11 years) and C (11 to <16 years): B: +15.8 PP, C: +15.9 PP. HbA1c improved significantly in groups C and D (16 to <26 years) (both

conclusionIn recent years, we found an increasing use of new diabetes technologies and an improvement in metabolic control (TiR) across all age groups.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1InsulinInsulin Infusion SystemsRegistriesAdolescentAdultAge FactorsAustriaChildChild, PreschoolContinuous Glucose MonitoringDatabases, FactualFemaleFollow-Up StudiesBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinautomated insulin deliverydiabetes patient follow uphybrid closed loopsensor augmented pump therapytype 1 diabetes

Identifiers

PMID36840616
PMCPMC11418416
OpenAlexW4321850921

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.